Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/219680
Title: The polygenic basis of relapse after a first episode of schizophrenia
Author: Segura, Alex G.
Prohens, Llucia
Gassó Astorga, Patricia
Rodríguez Ferret, Natalia
García Rizo, Clemente
Moreno-Izco, Lucía
Andreu-Bernabeu, Álvaro
Zorrilla, Iñaki
Mané Santacana, Anna
Rodriguez Jimenez, Roberto
Roldán Bejarano, Alexandra
Sarró, Salvador
Ibáñez, Ángela
Usall i Rodié, Judith
Sáiz, Pilar A
Cuesta, Manuel J.
Parellada, Mara
González-Pinto, Ana
Berrocoso, Esther
Bernardo Arroyo, Miquel
Mas, Sergi
Mezquida Mateos, Gisela
Arbelo, Néstor
De Matteis, Mario
Galvañ, Joaquin
Duque Guerra, Alejandra
Arias i Queralt, Laia
Pérez Bacigalupe, María
González Ortega, Itxaso
Toll Privat, Alba
Casanovas Martínez, Francesc
Sanchez Pastor, Luis
Valtueña, Mercedes
Pomarol-Clotet, Edith
García León, María Ángeles
Butjosa Molines, Anna
Rubio Abadal, Elena
Ribeiro, María
López-Ilundain, Jose M.
Saiz Ruiz, Jerónimo
León-Quismondo, Luis
Rivero, Olga
Ruiz, Pedro
Segarra Echevarría, Rafael
García-Portilla González, María Paz, 1962-
Keywords: Cognició
Malalties hereditàries
Esquizofrènia
Cognition
Genetic diseases
Schizophrenia
Issue Date: 19-Aug-2023
Publisher: Elsevier B.V.
Abstract: Little is known about genetic predisposition to relapse. Previous studies have linked cognitive and psychopathological (mainly schizophrenia and bipolar disorder) polygenic risk scores (PRS) with clinical manifestations of the disease. This study aims to explore the potential role of PRS from major mental disorders and cognition on schizophrenia relapse. 114 patients recruited in the 2EPs Project were included (56 patients who had not experienced relapse after 3 years of enrollment and 58 patients who relapsed during the 3-year follow-up). PRS for schizophrenia (PRS-SZ), bipolar disorder (PRS-BD), education attainment (PRS-EA) and cognitive performance (PRS-CP) were used to assess the genetic risk of schizophrenia relapse.Patients with higher PRS-EA, showed both a lower risk (OR=0.29, 95% CI [0.11-0.73]) and a later onset of relapse (30.96± 1.74 vs. 23.12± 1.14 months, p=0.007. Our study provides evidence that the genetic burden of neurocognitive function is a potentially predictors of relapse that could be incorporated into future risk prediction models. Moreover, appropriate treatments for cognitive symptoms appear to be important for improving the long-term clinical outcome of relapse.
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.euroneuro.2023.06.003
It is part of: European Neuropsychopharmacology, 2023, vol. 75, p. 80-92
URI: https://hdl.handle.net/2445/219680
Related resource: https://doi.org/10.1016/j.euroneuro.2023.06.003
ISSN: 0924-977X
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
828479.pdf927.68 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons